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Background: Critical to the success of cancer immunotherapies is the identification of 
appropriate target antigens. Cancer-testis antigens (CTAs) are ectopically expressed 
immunoprivileged antigens transcriptionally controlled by DNA methylation which have 
utility as immunotherapeutic targets. 5-azacytidine, an analogue of cytidine, has been 
shown to induce expression of CTAs in cancer. During the experiment, we analyzed 
matched samples from 42 myelodysplastic syndrome patients receiving an oral regimen 
of 5-azacytidine to determine if an anti-CTA immune response was generated.  
Methods: Immunoglobulin G (IgG) responses to a panel of 29 CTAs including NY-
ESO1, Mage-1, and SSX2 were analyzed by ELISA, Western Blot, and SEREX HTI 
procedures to identity novel responses. A standardization of human IgG, as well as a 
healthy donor control was used to determine the validity of identified responses. 
Results: We have confirmed prior studies which have identified immune responses to 
various CTAs in MDS patients. We will present novel findings including the induction of 
IgG responses in the responses to oral 5-azacytidine. 
Conclusions: Our findings suggest that CTAs could be further pursued as an 
immunotherapeutic target in myelodyplastic syndrome and that treatment with 5-
azacytidine could be exploited to modulate antigen expression in combination with 
immunotherapeutic approaches. 
 
